Avandia Safety Review Planned By U. Miami-Humana Data Mining Venture
Executive Summary
A safety analysis of GlaxoSmithKline's Avandia is among the first evaluations planned by a pharmacovigilance initiative announced by the University of Miami and Humana Aug. 22
You may also be interested in...
Avandia And Actos Add “Black Boxes” For Heart Failure
As an interim step in its ongoing review of thiazolidinedione cardiac safety, FDA has called for revised class labeling for the TZDs featuring strengthened warnings about the incidence of heart failure and contraindications for patients with existing heart failure
Sanofi Seeks Further FDA Input Following Zimulti NDA Withdrawal
Sanofi-Aventis intends to resubmit its NDA for Zimulti (rimonabant) pending clarification of FDA's questions regarding its obesity claim. The firm announced it was withdrawing the application June 29, roughly two weeks after the agency's Endocrinologic and Metabolic Drugs Advisory Committee unanimously voted against approval of the cannabinoid-1 receptor antagonist for weight loss
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.